PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
All content for PeerVoice Clinical Pharmacology Video is the property of PeerVoice and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
Patrick Vermersch, MD, PhD - Stripped Back: CNS Inflammation and the Potential for Meaningful Therapeutic Progress in Non-Relapsing Forms of Multiple Sclerosis
PeerVoice Clinical Pharmacology Video
49 minutes 24 seconds
1 month ago
Patrick Vermersch, MD, PhD - Stripped Back: CNS Inflammation and the Potential for Meaningful Therapeutic Progress in Non-Relapsing Forms of Multiple Sclerosis
Visit https://www.peervoice.com/HQU860 to view the entire programme with slides. After completing “Patrick Vermersch, MD, PhD - Stripped Back: CNS Inflammation and the Potential for Meaningful Therapeutic Progress in Non-Relapsing Forms of Multiple Sclerosis”, participants will be able to: Recognise the unmet needs and limitations of current treatment approaches in addressing disability and disease progression in patients with non-relapsing forms of multiple sclerosis (MS); Describe the mechanistic rationale for emerging therapies (eg, Bruton tyrosine kinase inhibitors [BTKi] and anti-CD40 ligand [CD40L] monoclonal antibodies) in the context of the pathophysiological drivers of central nervous system inflammation in primary progressive and non-relapsing secondary progressive MS; Discuss the design and patient populations associated with clinical trials examining emerging therapies in primary progressive and non-relapsing and secondary progressive MS; and Appraise the data from trials examining the safety and efficacy of emerging therapies (eg, BTKi and anti-CD40L monoclonal antibodies) in primary progressive and non-relapsing secondary progressive MS.
PeerVoice Clinical Pharmacology Video
PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
